Acceleron’s Sotatercept achieved primary and secondary endpoints in PULSAR trial in pulmonary arterial hypertension
In patients on stable background PAH-specific therapies, sotatercept demonstrated a statistically significant reduction in pulmonary vascular resistance (PVR), the trial’s primary endpoint, at week 24 versus placebo. The